iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020– EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020 – – EOS-448 has shown potent antitumor activity and a favourable tolerability profile in preclinical studies – Cambridge, MA and
iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020Cambridge, MA and Gosselies, Belgium – June 15, 2020. iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today that it will present
- Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A 2A adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers– First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials – – Initial clinical data expected in 1H 2021 –
btn News Archive
Disclaimer. This page contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements. iTeos assumes no obligation to update any forward-looking statements [on this page/in this press release] in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.